Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

ABLYNX TO PRESENT AT 2013 J.P. MORGAN HEALTHCARE CONFERENCE


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-07 18:14:37 -

GHENT,   Belgium,  7 January  2013 -  Ablynx  [Euronext  Brussels:  ABLX]  today
announces it will present at the 31(st) Annual J.P. Morgan Healthcare Conference
in  San Francisco, California on Thursday, 10(th) January 2013 at 12:00 p.m. PST
(21:00 p.m. CET).

The  presentation, followed by a Q&A, will be  hosted by Dr Edwin Moses, CEO and
Chairman  of Ablynx.  The presentation  will provide  an update on the Company's
late-stage proprietary Nanobody® programmes, the Company's growth and partnering
strategy and the outlook for the near term future.

The  presentation will be  webcast live and  can be accessed  on the day via the
Ablynx  website at www.ablynx.com. A replay of  the 
webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t:   +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /      +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t:   +44 207 920 2330 e:  ablynx@mcomgroup.com press release in pdf format: hugin.info/137912/R/1668728/541899.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Thomson Reuters ONE [HUG#1668728]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser